{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:44:12Z","timestamp":1790016252376,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal de Mycologie M\u00e9dicale"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.mycmed.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,3,10]],"date-time":"2018-03-10T20:13:56Z","timestamp":1520712836000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity"],"prefix":"10.1016","volume":"28","author":[{"given":"J.","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Ledoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nivoix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2018.02.005_bib0005","article-title":"Isavuconazole: a new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity","author":"Ledoux","year":"2017","journal-title":"J Med Mycol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/17460913.3.6.603","article-title":"Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections","volume":"3","author":"Guinea","year":"2008","journal-title":"Future Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0015","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0020","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0025","doi-asserted-by":"crossref","first-page":"571e1","DOI":"10.1016\/j.cmi.2016.01.017","article-title":"EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents","volume":"22","author":"Arendrup","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0030","doi-asserted-by":"crossref","first-page":"7882","DOI":"10.1128\/AAC.02107-15","article-title":"Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species","volume":"59","author":"Chowdhary","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0035","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1128\/JCM.00863-13","article-title":"In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0040","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0045","first-page":"61","article-title":"Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values","author":"Arendrup","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0050","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1128\/AAC.00685-10","article-title":"In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens","volume":"54","author":"Guinea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0055","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/JCM.02321-09","article-title":"Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia","volume":"48","author":"Guinea","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0060","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1128\/AAC.00646-08","article-title":"Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans","volume":"52","author":"Thompson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0065","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1179\/joc.2009.21.3.272","article-title":"In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries","volume":"21","author":"Verweij","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0075","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1128\/AAC.01111-13","article-title":"Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method","volume":"57","author":"Howard","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0080","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0085","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cmi.2017.03.023","article-title":"Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates","volume":"23","author":"Astvad","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/JCM.00367-15","volume":"53","author":"Kathuria","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0100","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1128\/AAC.01512-07","article-title":"In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species","volume":"52","author":"Guinea","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0110","first-page":"859","article-title":"In vitro combination therapy with isavuconazole against Candida spp","volume":"22","author":"Katragkou","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0115","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/AAC.00850-13","article-title":"Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii","volume":"57","author":"Hazirolan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0120","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/JCM.02222-08","article-title":"Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov","volume":"47","author":"Taj-Aldeen","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/dkp138","article-title":"In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species","volume":"64","author":"Thompson","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2010.06.003","article-title":"In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan","volume":"36","author":"Yamazaki","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0135","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/JCM.01190-13","article-title":"Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility","volume":"51","author":"Datta","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0140","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/JCM.06750-11","article-title":"Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population","volume":"50","author":"Hagen","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0145","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1128\/AAC.01384-07","article-title":"In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba","volume":"52","author":"Illnait-Zaragozi","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0150","doi-asserted-by":"crossref","first-page":"e32868","DOI":"10.1371\/journal.pone.0032868","article-title":"Resistance of Asian Cryptococcus neoformans serotype A is confined to few microsatellite genotypes","volume":"7","author":"Pan","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0155","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cid\/ciw305","article-title":"Isavuconazole treatment of Cryptococcosis and dimorphic mycoses","volume":"63","author":"Thompson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0160","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/myc.12507","article-title":"Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark","volume":"59","author":"Hagen","year":"2016","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.04055-14","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0170","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1128\/AAC.01530-08","article-title":"In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"53","author":"Perkhofer","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0175","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0180","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0185","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/j.1439-0507.2010.01996.x","article-title":"In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs","volume":"54","author":"Shivaprakash","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0190","doi-asserted-by":"crossref","first-page":"e00004","DOI":"10.1128\/AAC.00004-17","article-title":"Genetic diversity and in vitro antifungal susceptibility of 200\u00a0clinical and environmental Aspergillus flavus isolates","volume":"61","author":"Taghizadeh-Armaki","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dki399","article-title":"In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp","volume":"57","author":"Warn","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0200","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jac\/dkn076","article-title":"Activity of BAL 4815 against filamentous fungi","volume":"61","author":"Martin de la Escalera","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ijantimicag.2010.08.010","article-title":"The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and\/or immunosuppressed patients","volume":"36","author":"Perkhofer","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0210","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3389\/fmicb.2016.01382","article-title":"Epidemiological and genomic landscape of azole resistance mechanisms in Aspergillus fungi","volume":"7","author":"Hagiwara","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0215","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0220","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1093\/jac\/dku259","article-title":"Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania","volume":"69","author":"Chowdhary","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0225","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1128\/AAC.01355-13","article-title":"Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus","volume":"57","author":"Lepak","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0230","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1128\/AAC.03261-14","article-title":"In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds","volume":"58","author":"Katragkou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/myc.12234","article-title":"Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India","volume":"57","author":"Chowdhary","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/13693780802562969","article-title":"In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi","volume":"47","author":"Gonzalez","year":"2009","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0245","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0250","first-page":"1068","article-title":"Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex","volume":"70","author":"Al-Hatmi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0255","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1128\/JCM.00653-10","article-title":"Use of amplified fragment length polymorphism to identify 42 Cladophialophora strains related to cerebral phaeohyphomycosis with in vitro antifungal susceptibility","volume":"48","author":"Badali","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0260","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1128\/AAC.01655-09","article-title":"In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp","volume":"54","author":"Najafzadeh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0265","doi-asserted-by":"crossref","first-page":"7818","DOI":"10.1128\/AAC.01733-15","article-title":"In vitro susceptibility profiles of eight antifungal drugs against clinical and environmental strains of Phaeoacremonium","volume":"59","author":"Badali","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0270","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1128\/AAC.01629-13","article-title":"In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous Exophiala species","volume":"57","author":"Najafzadeh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0275","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.1128\/AAC.03095-14","article-title":"In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans","volume":"58","author":"Najafzadeh","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0280","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3109\/13693786.2011.583285","article-title":"Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist","volume":"49","author":"Badali","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0285","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1128\/AAC.00244-15","article-title":"Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum","volume":"59","author":"Deng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0290","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1128\/AAC.00742-16","article-title":"In vitro activity of isavuconazole against Rasamsonia species","volume":"60","author":"Steinmann","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.fgb.2015.02.009","article-title":"Recognition of seven species in the Cryptococcus gattii\/Cryptococcus neoformans species complex","volume":"78","author":"Hagen","year":"2015","journal-title":"Fungal Genet Biol"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0300","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1128\/AAC.00746-10","article-title":"In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates","volume":"54","author":"Hagen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0305","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s10096-016-2731-8","article-title":"Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6\/VGII) isolates from Southern Brazil","volume":"35","author":"Herkert","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2018.02.005_bib0310","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1128\/AAC.03779-14","article-title":"EUCAST testing of isavuconazole susceptibility in Aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density","volume":"58","author":"Arendrup","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal de Mycologie M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317304183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523317304183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:20:08Z","timestamp":1761110408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523317304183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1156523317304183"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.02.005","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity","name":"articletitle","label":"Article Title"},{"value":"Journal de Mycologie M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}